WHO: Evidence is lacking for clinical effectiveness of Xevudy and Regen-Cov against the COVID-19 variants that are currently circulating.
Pfizer announced that the first participants have been dosed in a novel phase 3 efficacy clinical trial of its quadrivalent modified RNA influenza vaccine candidate.
The performance of 3 commercially available COVID-19 home-testing kits worsened during the emergence of the omicron variant, according to a new cross-sectional study.
Get answers to 7 questions you may have regarding bivalent booster dose vaccination for patients from the US Centers for Disease Control and Prevention.
Steer clear of antibiotic Rxs whenever possible, says Anne Meneghetti, MD, to help the US get back to pre-COVID levels of antimicrobial stewardship.
Preventing viral infections with vaccination can keep the most vulnerable out of the hospital, reducing the risk of bacterial superinfections.
Only 9% of inpatients with COVID-19 had a bacterial superinfection that could be treated with antibiotics which curbed use of broad-spectrum antimicrobials.
Pfizer announced that a single dose of the vaccine, RSVpreF, demonstrated 85.7% efficacy against severe disease, defined by ≥3 symptoms.
Widespread antibiotic prescribing in the first year of the pandemic set back US progress on the fight against antimicrobial resistance, says Anne Meneghetti, MD.
A new real-world study found that two-thirds of patients with COVID-19 were still infectious 5 days and one-fourth at 7 days after symptom onset.